{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061084","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.296040+00:00","generated_at":"2026-06-08T09:50:44.558842+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Equillium Q3 net loss narrows to $3.7M; lupus trial meets endpoints","bullets":["Net loss $3.7M ($0.11 per share) vs $13.7M loss in Q3 2022, driven by $8.9M revenue from Ono partnership.","Cash $46.3M provides runway into 2025; net cash used in ops only $1.9M in Q3.","EQUALISE lupus nephritis data: 73% median UPCR reduction at Week 28; 40% CR, 33% PR; safety favorable.","Ono option decision triggered by data deliverables in early 2024; exercise would bring ~$33M payment.","EQ101 alopecia areata fully enrolled; initial data expected Q4 2023; EQ102 SAD/MAD data also Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061084","json":"https://secwatch.observer/filing/0000950170-23-061084.json","markdown":"https://secwatch.observer/filing/0000950170-23-061084.md","text":"https://secwatch.observer/filing/0000950170-23-061084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023061084/0000950170-23-061084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023061084/eq-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:50:44.558842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}